MX2023011610A - Proteinas de union a la proteina de muerte programada 1 (pd-1) y al inmunorreceptor de celulas con dominios de inmunoglobulina y motivos de inhibicion de inmunorreceptores a base de tirosina (tigit) biespecificas y usos de las mismas. - Google Patents

Proteinas de union a la proteina de muerte programada 1 (pd-1) y al inmunorreceptor de celulas con dominios de inmunoglobulina y motivos de inhibicion de inmunorreceptores a base de tirosina (tigit) biespecificas y usos de las mismas.

Info

Publication number
MX2023011610A
MX2023011610A MX2023011610A MX2023011610A MX2023011610A MX 2023011610 A MX2023011610 A MX 2023011610A MX 2023011610 A MX2023011610 A MX 2023011610A MX 2023011610 A MX2023011610 A MX 2023011610A MX 2023011610 A MX2023011610 A MX 2023011610A
Authority
MX
Mexico
Prior art keywords
binding proteins
bispecific
tigit binding
disclosure
uses therof
Prior art date
Application number
MX2023011610A
Other languages
English (en)
Inventor
Scott Hammond
Yariv Mazor
Yue Wang
Gordon Moody
Deepali Malhotra
Michael Overstreet
Eleanor Clancy-Thompson
Karin Lee
Stacy Pryts
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2023011610A publication Critical patent/MX2023011610A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La descripción se relaciona con proteínas de unión, que incluyen anticuerpos, que se unen a muerte programada 1 ("PD-1") y al inmunorreceptor de células T con dominios Ig e ITIM ("TIGIT"). La descripción también proporciona composiciones que comprenden tales proteínas de unión y moléculas de ácido nucleico que codifican tales proteínas de unión. La descripción también se relaciona con métodos para tratar un trastorno o afección usando tales proteínas de unión.
MX2023011610A 2021-04-30 2022-04-29 Proteinas de union a la proteina de muerte programada 1 (pd-1) y al inmunorreceptor de celulas con dominios de inmunoglobulina y motivos de inhibicion de inmunorreceptores a base de tirosina (tigit) biespecificas y usos de las mismas. MX2023011610A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163182156P 2021-04-30 2021-04-30
PCT/IB2022/053997 WO2022229919A2 (en) 2021-04-30 2022-04-29 Bispecific pd-1 and tigit binding proteins and uses therof

Publications (1)

Publication Number Publication Date
MX2023011610A true MX2023011610A (es) 2023-10-11

Family

ID=83846748

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011610A MX2023011610A (es) 2021-04-30 2022-04-29 Proteinas de union a la proteina de muerte programada 1 (pd-1) y al inmunorreceptor de celulas con dominios de inmunoglobulina y motivos de inhibicion de inmunorreceptores a base de tirosina (tigit) biespecificas y usos de las mismas.

Country Status (17)

Country Link
US (2) US11939382B2 (es)
EP (1) EP4329803A2 (es)
JP (1) JP2024517558A (es)
KR (1) KR20240004300A (es)
CN (1) CN117202933A (es)
AR (1) AR125488A1 (es)
AU (1) AU2022265633A1 (es)
BR (1) BR112023020193A2 (es)
CA (1) CA3212025A1 (es)
CL (1) CL2023002928A1 (es)
CO (1) CO2023013140A2 (es)
CR (1) CR20230476A (es)
EC (1) ECSP23074489A (es)
IL (1) IL307284A (es)
MX (1) MX2023011610A (es)
TW (1) TW202309086A (es)
WO (1) WO2022229919A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023215719A1 (en) * 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same
WO2024175699A1 (en) 2023-02-23 2024-08-29 Imcheck Therapeutics Combination of btn3a activating antibody and immune checkpoint inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR108377A1 (es) 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
EP3347379B9 (en) 2016-08-17 2020-03-25 Compugen Ltd. Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
KR20200120641A (ko) 2018-01-15 2020-10-21 난징 레전드 바이오테크 씨오., 엘티디. Pd-1에 대한 단일-도메인 항체 및 이의 변이체

Also Published As

Publication number Publication date
CN117202933A (zh) 2023-12-08
AR125488A1 (es) 2023-07-19
US20240287183A1 (en) 2024-08-29
CR20230476A (es) 2024-01-30
BR112023020193A2 (pt) 2023-11-14
EP4329803A2 (en) 2024-03-06
WO2022229919A2 (en) 2022-11-03
AU2022265633A9 (en) 2024-01-25
WO2022229919A3 (en) 2023-01-05
CA3212025A1 (en) 2022-11-03
CL2023002928A1 (es) 2024-04-12
JP2024517558A (ja) 2024-04-23
AU2022265633A1 (en) 2023-09-28
US20220411509A1 (en) 2022-12-29
KR20240004300A (ko) 2024-01-11
IL307284A (en) 2023-11-01
US11939382B2 (en) 2024-03-26
TW202309086A (zh) 2023-03-01
CO2023013140A2 (es) 2023-10-19
ECSP23074489A (es) 2023-12-29

Similar Documents

Publication Publication Date Title
MX2023011610A (es) Proteinas de union a la proteina de muerte programada 1 (pd-1) y al inmunorreceptor de celulas con dominios de inmunoglobulina y motivos de inhibicion de inmunorreceptores a base de tirosina (tigit) biespecificas y usos de las mismas.
MX2022009306A (es) Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
MX2023005375A (es) Anticuerpos trivalentes biespecificos unidos a claudina 6 o claudina 18.2 y cd3 para el tratamiento de enfermedades de cancer que expresan claudina.
DE602005022830D1 (de) Weniger immunogene bindungsmoleküle
EP4286415A3 (en) Humanized antigen-binding domains against cd19 and methods of use
UA83791C2 (ru) Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1
SG138469A1 (en) Antibodies to insulin-like growth factor i receptor
TW200716677A (en) Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
EA200701443A1 (ru) Синтетические домены иммуноглобулина, обладающие свойствами связывания и сконструированные в участках молекулы, отличных от гипервариабельных участков
WO2022006451A3 (en) Compositions and methods for tcr reprogramming using fusion proteins and pd-1 antibodies
MX2022001068A (es) Anticuerpo anti-il17a humanizado y uso del mismo.
MX2023009022A (es) Anticuerpos multiespecificos con especificidad para ror1 y cd3.
MX2021005323A (es) Metodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn.
MY189412A (en) Antibody to programmed cell death 1 (pd-1) and use thereof
MX2022006709A (es) Anticuerpos antiidiotípicos para dominios de unión dirigidos a bcma y métodos y composiciones relacionadas.
WO2021263167A3 (en) Il-10 muteins and fusion proteins thereof
MX2021013441A (es) Molecula de union a antigenos, composicion farmaceutica y metodo.
PE20232050A1 (es) Anticuerpos anti-cd19 y estructuras car-t
ATE544783T1 (de) Neutralisierende anti tlr4/md-2 antikörper und verfahren zu deren verwendung
MX2023006969A (es) Moleculas de union a gucy2c y sus usos.
MX2021010577A (es) Compuestos de union a pd-l1 multivalentes para tratar cancer.
MX2023014666A (es) Agentes aglutinantes biespecificos que se unen a cldn18.2 y cd3.
MX2022011801A (es) Anticuerpos monoclonales contra acidos nucleicos modificados quimicamente y usos de los mismos.
MX2022001882A (es) Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
NO20064183L (no) Mindre immunogene bindingsmolekyler